biospace AstraZeneca today announced the results oMarch 20, 2018
Tag: AstraZeneca , Diabetes
AstraZeneca today announced the results of DERIVE, a Phase 3 study that evaluated the efficacy and safety of FARXIGA®(dapagliflozin 10 mg), in patients with type 2 diabetes (T2D) with moderate renal impairment (chronic kidney disease [CKD] stage 3A with eGFR of 45-59 mL /min /1 .73m2). The results were presented at the Endocrine Society’s 100th Annual Meeting and Expo (ENDO).
FARXIGA, an SGLT2 inhibitor, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2D mellitus.1 FARXIGA is not indicated for weight loss or for the treatment of CKD or hypertension.
The DERIVE trial randomized 321 patients with T2D (hemoglobin A1C [HbA1C] between 7-11%; mean 8.2%) and stage 3A CKD (mean estimated glomerular filtration rate [eGFR] 53 mL/min/1.73m2) from eight countries and treated them with either dapagliflozin 10 mg or placebo over 24 weeks.2 The study met its primary and secondary efficacy endpoints including:
The DERIVE trial also provides the following safety information:
FARXIGA is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m2), end-stage renal disease, or in patients on dialysis. FARXIGA is not recommended in patients with an eGFR persistently between 30 and <60 mL/min/1.73 m2. The recommended starting dose for FARXIGA is 5 mg.
Jim McDermott, PhD, Vice President, US Medical Affairs, Diabetes at AstraZeneca, said: "We are committed to helping patients with complex and comorbid diseases like T2D and chronic kidney disease, which is demonstrated through the breadth of our research and our unique cardiovascular, renal and metabolic approach. The DERIVE study will help us learn more and provide additional data for FARXIGA in T2D."
DERIVE adds important information to previous dapagliflozin studies in patients with T2D diabetes and moderate renal impairment. AstraZeneca is planning to submit the results of DERIVE to the FDA to add to the breadth of data already contained within the existing FARXIGA Prescribing Information.
According to the Centers for Disease Control and Prevention, 30.3 million people in the US have diabetes, and T2D accounts for 90% to 95% of all diabetes cases.3 T2D is the leading cause of CKD in the US, affecting over 40% of patients, and sustaining control of diabetes can help lower patients risk of developing severe kidney disease.4, 5
Important Safety Information for FARXIGA® (dapagliflozin)
Contraindications
Warnings and Precautions
Adverse Reactions
In a pool of 12 placebo-controlled studies, the most common adverse reactions (≥5%) associated with FARXIGA 5 mg, 10 mg, and placebo respectively were female genital mycotic infections (8.4% vs 6.9% vs 1.5%), nasopharyngitis (6.6% vs 6.3% vs 6.2%), and urinary tract infections (5.7% vs 4.3% vs 3.7%).
Use in Specific Populations
Indication and Limitations of Use for FARXIGA® (dapagliflozin)
FARXIGA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
FARXIGA is not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
NOTES TO EDITORS
About AstraZeneca in Diabetes
AstraZeneca is pushing the boundaries of science with the goal of developing life-changing medicines that aim to reduce the global burden and complications of diabetes. As a main therapy area for the company, we are focusing our research and development efforts on diverse populations and patients with significant co-morbidities, such as cardiovascular disease, obesity, non-alcoholic steatohepatitis (NASH), and chronic kidney disease.
Our commitment to diabetes is exemplified by the depth and breadth of our global clinical research program. This commitment is advancing the understanding of the treatment effects of our diabetes medicines in broad patient populations, as well as exploring combination products to help more patients achieve treatment success earlier in their disease.
About AstraZeneca in Cardiovascular, Renal & Metabolic Diseases
Cardiovascular, renal and metabolic diseases together form one of AstraZeneca’s main therapy areas and platforms for future growth. By following the science to understand more clearly the underlying links between the heart, kidney and pancreas, AstraZeneca is investing in the development of a portfolio of medicines to protect organs and improve outcomes by slowing disease progression, reducing risks and tackling co-morbidities. Our ambition is to modify or halt the natural course of CVMDs and even regenerate organs and restore function, by continuing to deliver transformative science that improves treatment practices and CVMD health for millions of patients worldwide.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: